The company’s adjusted earnings excluded $900,000 in after-tax charges related to the J&J’s acquisition of Synthes, in-process R&D and an increase in the accrual for litigation expenses.
J&J boosted its earnings guidance for the full year from an adjusted EPS range of $5.40 to $5.47 to a new range of $5.44 to $5.49. The consensus estimate had called for EPS of $5.46 on revenues of $70.81 billion. For the first nine months of the year, the company has posted revenues of $52.96 billion and diluted adjusted EPS of $4.28.
The firm’s CEO said:
Our third-quarter results reflect the solid, demonstrable results in achieving our near-term priorities while also advancing our longer term strategic growth drivers. Our key products and successful new product launches delivered strong growth. We continue to progress our pipelines with a number of regulatory approvals, the submission of new drug applications, and execution of strategic collaborations.
Worldwide consumer sales rose 0.8% year-over-year to $3.61 billion, including a negative currency impact of 1.2%. Pharmaceutical sales rose 9.9% to $7.04 billion. Medical devices and diagnostics sales fell 2% to $6.93 billion. The negative currency exchange impact on total revenues was 1.6% in the quarter.
Although sales totals were higher in each of the company’s segments, year-over-year growth did not match second-quarter growth in any of them. Consumer sales in the second quarter were up 1.1%, drug sales were up 11.7%, and devices and diagnostics sales were up 9.6%. For all the happy talk, this is not a good sign.
Shares are trading about 1% higher in the premarket Tuesday morning, at $91.45 in a 52-week range of $68.51 to $94.42. Thomson Reuters had a consensus analyst price target of around $94.10 before these results were announced.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
